| Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. | |
| | |
MedLine Citation:
|
PMID: 17315055 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND OBJECTIVE: Inhaled beta-agonist, anticholinergic and glucocorticoid medications are used to treat asthma and chronic obstructive pulmonary disease (COPD). The present study assessed the patterns of persistence with the above mentioned inhaled medications. METHODS: Prescription claims data from the Ontario Drug Benefit Program were analyzed to assess persistence (time to discontinuation) and compliance (percentage of days with doses available divided by days to last refill) of patients prescribed inhaled medications. Patients were grouped as naive (no inhaled medication in the previous year) or experienced (previous or current treatment), and by age (18 to 65 years of age and older than 65 years of age). Medications included ipratropium, ipratropium plus salbutamol, formoterol, formoterol plus budesonide, salmeterol, salmeterol plus fluticasone, and tiotropium. RESULTS: The database included 31,368 patients (4888 naive and 26,480 experienced) who were prescribed at least one of these medications. Fifteen per cent to 63% of patients continued on the index drug for more than six months, which decreased to 7% to 53% at 12 months, and 5% to 47% at 18 months. At 12 months, patients taking tiotropium had significantly longer persistence compared with other therapies (53% versus 7% to 30%; all P<0.0001), and fewer switches to alternative medications. Most naive patients had significantly shorter treatment persistence than experienced patients for all drugs (all P<0.0001), including tiotropium (27% versus 55%, P<0.0001). Compliance rates were similar for all drugs (ie, 76% to 94%) but were highest for tiotropium. CONCLUSIONS: These data demonstrated that persistence with inhaled treatment was low overall, but patients treated with tiotropium remained on therapy significantly longer than when treated with other medications, and patients naive to inhaled treatment had shorter treatment persistence than experienced patients. |
| | |
Authors:
|
Joyce A Cramer; Carole Bradley-Kennedy; Alissa Scalera |
Related Documents
:
|
1137255 - Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: c... 19668045 - An unusual complication: prolonged myopathy due to an alternative medical therapy with ... 8452575 - Chlorambucil. an effective corticosteroid-sparing agent for patients with recalcitrant ... 17422385 - Canine pemphigus vulgaris treated with gold salt therapy. 9017615 - Late diagnosis of chronic renal failure and mortality on maintenance dialysis. 16979745 - Percutaneous treatment of large upper tract stones after urinary diversion. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Canadian respiratory journal : journal of the Canadian Thoracic Society Volume: 14 ISSN: 1198-2241 ISO Abbreviation: Can. Respir. J. Publication Date: 2007 Jan-Feb |
Date Detail:
|
Created Date: 2007-02-22 Completed Date: 2007-04-11 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 9433332 Medline TA: Can Respir J Country: Canada |
Other Details:
|
Languages: eng Pagination: 25-9 Citation Subset: IM |
Affiliation:
|
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06516-2770, USA. joyce.cramer@yale.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Inhalation Adrenergic beta-Agonists / administration & dosage, therapeutic use* Aged Aged, 80 and over Albuterol / administration & dosage, analogs & derivatives, therapeutic use Bronchodilator Agents / administration & dosage, therapeutic use* Budesonide / administration & dosage, therapeutic use Cholinergic Antagonists / administration & dosage, therapeutic use* Drug Therapy, Combination Ethanolamines / administration & dosage, therapeutic use Female Glucocorticoids / administration & dosage, therapeutic use* Humans Ipratropium / administration & dosage, therapeutic use Male Middle Aged Patient Compliance / statistics & numerical data* Pulmonary Disease, Chronic Obstructive / drug therapy* Scopolamine Derivatives / administration & dosage, therapeutic use Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Agonists; 0/Bronchodilator Agents; 0/Cholinergic Antagonists; 0/Ethanolamines; 0/Glucocorticoids; 0/Scopolamine Derivatives; 136310-93-5/tiotropium; 18559-94-9/Albuterol; 51333-22-3/Budesonide; 60205-81-4/Ipratropium; 73573-87-2/formoterol; 89365-50-4/salmeterol |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Postoperative outcome after coronary artery bypass grafting in chronic obstructive pulmonary disease...
Next Document: Density functional theory with dispersion corrections for supramolecular structures, aggregates, and...